1. GPCR/G Protein Neuronal Signaling
  2. GPR119
  3. YH18968

YH18968 是一种口服有效的 GPR119 激活剂,其诱导 cAMP 积累的 EC50 为 2.8 nM。YH18968 可激活 GPR119,升高细胞内环磷酸腺苷水平,刺激肠道 L 细胞分泌胰高血糖素样肽-1,并触发胰腺 β 细胞分泌葡萄糖依赖性胰岛素。YH18968 可改善正常小鼠和饮食诱导肥胖小鼠的葡萄糖耐量。YH18968 可用于 2 型糖尿病的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

YH18968

YH18968 Chemical Structure

CAS No. : 1632498-56-6

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

YH18968 is an orally active GPR119 agonist with an EC50 of 2.8 nM for inducing cAMP accumulation. YH18968 activates GPR119, elevates intracellular cyclic adenosine monophosphate levels, stimulates glucagon-like peptide-1 secretion from intestinal L cells, and triggers glucose-dependent insulin secretion from pancreatic β cells. YH18968 improves glucose tolerance in normal mice and diet-induced obese mice. YH18968 can be used for the research of type 2 diabetes[1].

体外研究
(In Vitro)

YH18968 (0.03-1000 nM; 60 min) 可以剂量依赖的方式刺激 HIT-T15 细胞分泌胰岛素,其 EC50 为 3.5 nM[1]
YH18968 (0.03-1000 nM; 120 min) 可以剂量依赖的方式刺激 GLUTag 细胞分泌 GLP-1,其 EC50 为 0.1 nM[1]
YH18968 (0.1-100 μM; 48 h) 在 HIT-T15、GLUTag 和 HepG2 细胞中的细胞毒性极低,三种细胞系中的 LC50 均大于 100 μM[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay[1]

Cell Line: HIT-T15 hamster insulinoma cells
Concentration: 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, and 1,000 nM nM (15 mM glucose condition); 100 nM (0, 3, or 15 mM glucose conditions)
Incubation Time: 60 min
Result: Elicited dose-dependent increases in insulin release with an EC50 of 3.5 nM.
Enhanced insulin release in a glucose-dependent manner at 100 nM, with a significant increase observed at 15 mM glucose (2.19-fold vs control) and no effect in the absence of glucose.

ELISA Assay[1]

Cell Line: GLUTag murine intestinal L cells
Concentration: 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, and 1,000 nM
Incubation Time: 120 min
Result: Enhanced GLP-1 secretion in a dose-dependent manner with an EC50 of 0.1 nM.
药代动力学
(Parmacokinetics)
Species Dose Route AUClast AUC0-inf CL Vss MRT Cmax Tmax T1/2 F
Mice[1] 1 mg/kg i.v. 1375.1 ng·h/mL 1619.9 ng·h/mL 617.3 mL/h/kg 2112.2 mL/kg 3.4 h / / / /
Mice[1] 1 mg/kg p.o. 549.7 ng·h/mL 719.8 ng·h/mL / / / 168.6 ng/mL 0.5 h 3.1 h 40.0 %
Mice[1] 10 mg/kg p.o. 2471.7 ng·h/mL 2958.2 ng·h/mL / / / 759.7 ng/mL 0.5 h 2.6 h 18.0 %
Mice[1] 100 mg/kg p.o. 6538.0 ng·h/mL 15773.9 ng·h/mL / / / 1472.2 ng/mL 0.5 h 9.2 h 4.8 %
体内研究
(In Vivo)

YH18968 (0.1-10 mg/kg;口服;单次给药) 可呈剂量依赖性改善正常 C57BL/6J 小鼠的葡萄糖耐量[1]
YH18968 (0.1-10 mg/kg;口服;单次给药) 可显著改善 DIO 小鼠的葡萄糖耐量,其药效在 1 mg/kg 时达到饱和[1]
YH18968 (1 mg/kg;口服;每日 1 次;连续 28 天) 维持 DIO 小鼠的葡萄糖耐量改善,且无快速减敏现象,与 Linagliptin (HY-10284) 联合使用时具有叠加效应[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (8-week-old, male)[1]
Dosage: 0.1 mg/kg; 1 mg/kg; 10 mg/kg; 10 mg/kg + 1 mg/kg linagliptin
Administration: p.o.; single dose
Result: Significantly lowered the 2-hour area under the curve (AUC) for blood glucose in a dose-dependent manner compared to vehicle control.
Produced a significant additive glucose-lowering effect when co-administered with 1 mg/kg linagliptin.
Increased active plasma GLP-1 levels by 2.7-fold compared to vehicle control at 30 minutes post-administration at 10 mg/kg dose.
Co-administration with linagliptin significantly increased active GLP-1 levels compared to either agent alone.
Animal Model: diet-induced obese (DIO) (17-week-old, male, Type 2 diabetes model)[1]
Dosage: 0.1 mg/kg; 1 mg/kg; 10 mg/kg
Administration: p.o.; single dose
Result: Significantly lowered the 2-hour AUC for blood glucose compared to vehicle control at 1 and 10 mg/kg doses, with a dose-dependent effect observed.
Produced similar levels of glucose lowering at 1 and 10 mg/kg doses, indicating a saturated effect.
Animal Model: diet-induced obese (DIO) (17-week-old, male, Type 2 diabetes model)[1]
Dosage: 1 mg/kg; 1 mg/kg + 1 mg/kg linagliptin
Administration: p.o.; once daily; 28 days
Result: Significantly lowered the 2-hour AUC for blood glucose compared to vehicle control on day 1, with a more potent effect than 10 mg/kg MBX2982 (HY-15291).
Produced an additive glucose-lowering effect when co-administered with 1 mg/kg linagliptin compared to either agent alone on day 1.
Continued to effectively lower the 2-hour AUC for blood glucose on day 29, maintaining glucose tolerance improvement equivalent to day 1 efficacy when used alone or in combination with Linagliptin.
分子量

545.58

Formula

C27H28FN9O3

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
YH18968
目录号:
HY-125646
需求量: